WG-1025

Phase I: Primary study objectives To evaluate the safety and tolerability of WG1025 in the treatment of dystrophic epidermolysis bullosa (DEB). Secondary study objectives To evaluate the preliminary efficacy of WG1025 in the treatment of DEB. To evaluate the pharmacokinetics of WG1025. To evaluate the immunogenicity of WG1025. In DEB patients, the expression of COL7A1 before and after treatment. Phase II Primary study objectives To evaluate the efficacy of WG1025 in the treatment of DEB. Secondary study objectives To evaluate the efficacy of WG1025 in the treatment of DEB. To evaluate the safety of WG1025 in the treatment of DEB. To evaluate the pharmacokinetics of WG1025. To evaluate the immunogenicity of WG1025 in DEB patients. In DEB patients, the expression of COL7A1 before and after treatment. Extension phase study objectives To evaluate the safety of WG1025 in the long-term treatment of DEB.